Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$2.70 -3.2%	$2.66	$2.12 ▼ $5.80	$268.19M	2.02	1.51 million shs	753,836 shs
GLUE Monte Rosa Therapeutics	$4.14 -2.1%	$4.41	$3.21 ▼ $12.40	$254.65M	1.52	1.06 million shs	465,211 shs
OKYO OKYO Pharma	$1.85 -1.3%	$1.40	$0.81 ▼ $1.98	$62.47M	-0.38	131,055 shs	16,195 shs
TVGN Tevogen Bio	$1.29 -4.1%	$1.09	$0.26 ▼ $3.09	$236.30M	-0.82	5.01 million shs	1.60 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+2.20%	+21.83%	-1.76%	-0.36%	-9.12%
GLUE Monte Rosa Therapeutics	+4.19%	+4.44%	-11.69%	-23.09%	+5.75%
OKYO OKYO Pharma	+1.08%	+1.63%	+17.98%	+48.42%	+33.57%
TVGN Tevogen Bio	+2.29%	+8.94%	+32.67%	+4.69%	+68.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.2397 of 5 stars	3.5	1.0	2.3	0.0	0.0
GLUE Monte Rosa Therapeutics	2.1623 of 5 stars	3.4	0.0	2.7	3.3	0.6
OKYO OKYO Pharma	2.6885 of 5 stars	3.5	5.0	2.2	1.7	0.0
TVGN Tevogen Bio	3.7823 of 5 stars	3.5	4.0	2.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.67	295.06% Upside
GLUE Monte Rosa Therapeutics	2.75	Moderate Buy	$15.50	274.40% Upside
OKYO OKYO Pharma	3.00	Buy	$7.00	279.14% Upside
TVGN Tevogen Bio	3.00	Buy	$7.10	452.53% Upside

Current Analyst Ratings Breakdown

Latest OKYO, GLUE, AQST, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/12/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/5/2025	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/29/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/21/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/2/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/21/2025	GLUE Monte Rosa Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$11.00 ➝ $10.00
3/20/2025	GLUE Monte Rosa Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
3/12/2025	GLUE Monte Rosa Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
3/11/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$54.23M	4.95	N/A	N/A	($1.59) per share	-1.70
GLUE Monte Rosa Therapeutics	$159.49M	1.60	N/A	N/A	$3.58 per share	1.16
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.20) per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($1.10) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$7.87M	-$0.59	N/A	N/A	N/A	-59.75%	N/A	-33.96%	8/5/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$135.35M	$0.08	N/A	N/A	N/A	N/A	-62.68%	-38.83%	8/14/2025 (Estimated)
OKYO OKYO Pharma	-$16.83M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	-$70K	N/A	0.00	∞	N/A	N/A	-396.07%	749.97%	N/A

Latest OKYO, GLUE, AQST, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
3/20/2025	Q4 2024	GLUE Monte Rosa Therapeutics	-$0.37	$0.23	+$0.60	$0.23	$43.73 million	$14.00 million
3/5/2025	Q4 2024	AQST Aquestive Therapeutics	-$0.14	-$0.19	-$0.05	-$0.19	$13.11 million	$11.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	6.37	5.91
GLUE Monte Rosa Therapeutics	N/A	6.03	6.03
OKYO OKYO Pharma	N/A	0.28	N/A
TVGN Tevogen Bio	N/A	0.34	0.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
GLUE Monte Rosa Therapeutics	79.96%
OKYO OKYO Pharma	2.97%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
GLUE Monte Rosa Therapeutics	6.90%
OKYO OKYO Pharma	40.46%
TVGN Tevogen Bio	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	84.02 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.44 million	Optionable
OKYO OKYO Pharma	7	33.84 million	20.15 million	Not Optionable
TVGN Tevogen Bio	3	183.89 million	75.97 million	N/A

OKYO, GLUE, AQST, and TVGN Headlines

Recent News About These Companies

Tevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI Technologies

May 30 at 11:20 AM | quiverquant.com

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

May 30 at 11:01 AM | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Earns Buy Rating from D. Boral Capital

May 29 at 1:15 AM | americanbankingnews.com

Tevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral Capital

May 28 at 8:15 AM | marketbeat.com

Tevogen Peports Plans to Increase the Target Population for TVGN 489

May 26, 2025 | msn.com

Tevogen expands target for COVID treatment to seniors

May 24, 2025 | investing.com

Tevogen Bio Inc: Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to ...

May 24, 2025 | finanznachrichten.de

Tevogen breidt doelgroep voor COVID-behandeling uit naar 65-plussers

May 23, 2025 | nl.investing.com

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

May 23, 2025 | globenewswire.com

Tevogen Bio Holdings Inc. to Provide Key Updates Ahead of Annual Meeting on June 23, 2025

May 22, 2025 | quiverquant.com

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

May 22, 2025 | globenewswire.com

D. Boral Capital Reiterates "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)

May 14, 2025 | marketbeat.com

Tevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical Competition

May 13, 2025 | nasdaq.com

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

May 12, 2025 | globenewswire.com

Tevogen Bio Holdings Inc. Announces Letter of Intent with CD8 Technology Services for Cell Therapy Manufacturing Facility

May 2, 2025 | nasdaq.com

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

May 2, 2025 | globenewswire.com

D. Boral Capital Reaffirms "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)

May 1, 2025 | marketbeat.com

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

April 30, 2025 | uk.finance.yahoo.com

Why Tevogen Bio Holdings Inc.’s (TVGN) Stock Is Up 5.60%

April 30, 2025 | aaii.com

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

April 30, 2025 | globenewswire.com

Tevogen Bio shares surge on revenue forecast

April 29, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO, GLUE, AQST, and TVGN Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$2.70 -0.09 (-3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$2.70 +0.00 (+0.19%)

As of 07:46 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.14 -0.09 (-2.13%)

Closing price 04:00 PM Eastern

Extended Trading

$4.10 -0.04 (-1.06%)

As of 05:43 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

OKYO Pharma NASDAQ:OKYO

$1.85 -0.02 (-1.27%)

Closing price 03:59 PM Eastern

Extended Trading

$1.87 +0.02 (+1.28%)

As of 06:01 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Tevogen Bio NASDAQ:TVGN

$1.28 -0.06 (-4.10%)

Closing price 04:00 PM Eastern

Extended Trading

$1.30 +0.02 (+1.56%)

As of 07:45 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time